骨生技藥品市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、最終用戶、地區和競爭對手分類，2021-2031年

全球骨生物製藥市場預計將從 2025 年的 212.3 億美元成長到 2031 年的 257.8 億美元，複合年成長率為 3.29%。

這些生物材料，包括骨移植材料、生長因子和幹細胞，對於促進整形外科和脊椎手術中的骨骼癒合和再生至關重要。市場擴張的主要驅動力是與老化相關的退化性肌肉骨骼疾病的日益普遍，以及需要重組手術的創傷性損傷發生率的上升。近期的手術量數據也印證了這項成長需求。根據美國脊椎註冊中心的數據，到2025年，註冊手術量將比前一年成長17.86%，凸顯了依賴這些生物解決方案的手術需求日益成長。

儘管市場成長迅速，但仍面臨許多挑戰，包括嚴格的法規結構和複雜的報銷機制。衛生監管機構嚴格的臨床試驗要求和漫長的核准流程常常導致產品上市延遲，並推高研發成本。此外，高成本生物製藥的醫保覆蓋範圍不統一，往往限制了患者的用藥途徑和接受度，這給尋求拓展全球醫療保健業務的製造商帶來了巨大障礙。

市場促進因素

骨生物製藥市場成長的主要促進因素是骨質疏鬆症和退化性骨病變的日益普遍。在高齡化社會中，這些疾病導致脆性骨折需要手術治療。隨著老齡化，骨骼密度自然下降，脊椎融合手術和骨折修復的成功越來越依賴能夠促進有效骨再生和骨整合的骨生物製劑。 2024年10月，國際骨質疏鬆症基金會報告稱，全球55歲及以上人群每年發生多達3,700萬例脆性骨折。這凸顯了對有效骨移植替代方案的持續且顯著的需求，因此，整形外科手術中對脫礦骨基質和合成移植物的需求穩步成長，以確保機械穩定性和良好的癒合效果。

此外，骨移植替代材料和生長因子的技術進步為傳統自體骨移植提供了更優的替代方案，顯著推動了市場發展。外科醫生擴大採用先進的合成生物製劑和細胞骨基質，這些材料能夠減少供體部位併發症，並在複雜的重組手術中實現可靠的骨誘導。這種臨床偏好的轉變也反映在主要產業參與者的財務表現上。 Orthofix Medical Inc. 公佈，其骨生長治療業務部門2024年第四季淨銷售額創歷史新高，達6,390萬美元，較去年同期成長9%。同時，Stryker 公佈其2024年全年整形外科部門淨銷售額為91億美元，這兩家公司都清楚地展現了利用這些創新生物解決方案的外科手術環境的強大商業性規模。

市場挑戰

全球骨生技藥品市場面臨許多挑戰，主要源自於嚴格的法規結構和日益嚴峻的醫保報銷環境。製造商必須謹慎應對複雜的核准流程，該流程要求提供大量的臨床證據來證明產品的安全性和有效性，這不可避免地導致研發週期延長和成本顯著增加。這些強大的監管障礙有效地阻礙了新型生技藥品的上市，從而使企業無法快速掌握市場機遇，並減緩了該領域的整體創新步伐。

此外，醫療機構面臨的日益成長的財務壓力也是限制市場發展的因素，直接影響採購決策。整形外科手術報銷率的降低迫使醫院優先考慮更經濟的替代方案，而不是高成本的生物製藥。近期行業數據顯示，這種財務壓力顯而易見。 2024年，美國整形外科學會指出，美國醫療保險和醫療補助服務中心已最終確定，2025年醫師報銷率將下調約2.83%。這種支付模式的下調構成了重大的經濟障礙，阻礙了先進骨生物療法的廣泛應用，從而限制了其市場滲透率。

市場趨勢

將奈米技術應用於骨整合以增強骨整合，正在從根本上改變產品開發。製造商現在正致力於設計移植材料的表面，使其能夠精細地模擬天然骨骼的層級結構。透過在分子層面精確控制材料，這些新一代基質顯著增加了細胞附著和增殖的表面積，從而加速了難治性脊椎和整形外科骨不連的融合速度。這項技術進步正迅速獲得商業性認可。 OssDesign AB 在 2024 年財務報告中指出，其奈米合成骨移植材料「Catalyst」的淨銷售額達到 1.339 億瑞典克朗，年成長高達 107%。

同時，骨生物製藥市場在牙科和顱顎顏面外科領域的應用日益廣泛，已超越了傳統的整形外科用途。臨床醫生在諸如牙槽骨保存和鼻竇增高術等關鍵手術中，越來越依賴先進的再生材料，以確保足夠的骨量用於即時植入，從而為現有市場參與企業拓展了收入來源。這種需求的激增體現在牙科行業主要企業的強勁業績上。例如，士卓曼集團2024年全年報告顯示，植入和生物材料產品組合實現了兩位數的內部成長，總銷售額達到25億瑞士法郎。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球骨生技藥品市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類別（同種異體移植、骨髓抽吸物濃縮液、骨形態發生骨形成蛋白、去礦物質骨基質、多聚血漿蛋白、合成骨科生技藥品、黏彈性替代產品）
  • 依應用領域（骨折恢復、顎顏面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合手術）
  • 按最終使用者（牙科診所/機構、醫院、研究/學術機構、專科診所、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美骨生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲骨生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區骨生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲骨生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美骨生技藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球骨生技藥品市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Stryker Corp
• DePuy Synthes Inc
• Medtronic PLC
• Osteomed LP
• Zimmer Biomet Holdings, Inc.
• Smith & Nephew plc
• Genzyme Corporation
• Arthrex Inc
• Orthofix International BV

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Osteobiologics Market is projected to grow from USD 21.23 Billion in 2025 to USD 25.78 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 3.29%. These biological materials, encompassing bone grafts, growth factors, and stem cells, are critical for accelerating bone healing and regeneration in orthopedic and spinal surgeries. The market's expansion is primarily fueled by an increasing prevalence of degenerative musculoskeletal conditions within an aging demographic and a rising incidence of traumatic injuries requiring reconstructive surgical interventions. This escalating demand is substantiated by recent surgical volume data, with the American Spine Registry reporting a 17.86% increase in submitted procedures in 2025 compared to the previous year, highlighting the growing need for operations relying on these biologic solutions.

Despite this growth, the market faces significant hurdles from stringent regulatory frameworks and complex reimbursement landscapes. Rigorous clinical trial requirements and protracted approval processes imposed by health authorities often delay product launches and inflate development expenses. Furthermore, inconsistent insurance coverage for high-cost biologic therapies frequently restricts patient access and adoption rates, thereby creating a substantial barrier for manufacturers aiming to expand their presence in the global healthcare sector.

Market Driver

A primary catalyst for the osteobiologics market's growth is the increasing prevalence of osteoporosis and degenerative bone diseases, which necessitate surgical intervention for fragility fractures in an aging population. As bone density naturally declines with age, the successful outcome of spinal fusions and fracture repairs becomes highly dependent on osteobiologic materials that stimulate effective bone regeneration and integration. The International Osteoporosis Foundation reported in October 2024 that up to 37 million fragility fractures occur annually worldwide in individuals over 55, underscoring a continuous and substantial need for effective bone graft substitutes, which in turn drives the consistent consumption of demineralized bone matrices and synthetic grafts in orthopedic procedures to ensure mechanical stability and proper healing.

Moreover, technological advancements in bone graft substitutes and growth factors are significantly propelling the market forward by providing superior alternatives to traditional autografts. Surgeons are increasingly adopting advanced synthetic biologics and cellular bone matrices, which mitigate donor site morbidity and offer reliable osteoinductive properties for complex reconstructions. This shift in clinical preference is reflected in the financial performance of key industry players; Orthofix Medical Inc. reported record net sales of $63.9 million for its Bone Growth Therapies segment in Q4 2024, a 9% year-over-year increase, while Stryker recorded full-year 2024 Orthopaedics net sales of $9.1 billion, collectively demonstrating the robust commercial scale of the procedural environment leveraging these innovative biologic solutions.

Market Challenge

The Global Osteobiologics Market encounters considerable obstacles stemming from stringent regulatory frameworks and an increasingly restrictive reimbursement environment. Manufacturers must meticulously navigate complex approval processes demanding extensive clinical evidence to substantiate both safety and efficacy, which inevitably prolongs development timelines and significantly escalates costs. These formidable regulatory barriers effectively impede the commercial introduction of novel biologic products, thereby preventing companies from promptly capitalizing on market opportunities and decelerating the overall pace of innovation within the sector.

Furthermore, the market is constrained by intensified financial pressures on healthcare providers, directly impacting procurement decisions. Reductions in reimbursement rates for orthopedic procedures compel hospitals to prioritize more economical alternatives over high-cost biologic materials. This financial strain is evident in recent industry data; the American Academy of Orthopaedic Surgeons noted in 2024 that the Centers for Medicare & Medicaid Services finalized a conversion factor reduction of approximately 2.83% for the 2025 physician fee schedule. Such downward adjustments in payment models create substantial economic hurdles, discouraging the widespread adoption of advanced osteobiologic therapies and consequently hindering their broader market penetration.

Market Trends

The integration of nanotechnology for enhanced osteointegration is fundamentally transforming product development, as manufacturers now engineer graft surfaces to intricately mimic the hierarchical structure of natural bone. By precisely manipulating materials at the molecular level, these next-generation matrices significantly augment the surface area available for cellular attachment and proliferation, consequently accelerating fusion rates in challenging spinal and orthopedic non-unions. This technological evolution is rapidly gaining commercial momentum, with OssDsign AB reporting net sales of SEK 133.9 million for its nanosynthetic bone graft Catalyst in its 2024 year-end report, marking a substantial 107% increase compared to the previous year.

Concurrently, the osteobiologics market is witnessing an expanding application in dental and craniomaxillofacial surgery, thereby broadening its scope beyond conventional orthopedic uses. Clinicians are increasingly relying on advanced regenerative materials for essential procedures such as ridge preservation and sinus lifts to ensure adequate bone volume for immediate implant placement, effectively diversifying revenue streams for established market participants. This surge in demand is reflected in the strong performance of major dental industry players, as evidenced by Straumann Group's 2024 full-year report, which showed total revenue of CHF 2.5 billion, driven by double-digit organic growth across its implantology and biomaterials portfolio.

Key Market Players

• Stryker Corp
• DePuy Synthes Inc
• Medtronic PLC
• Osteomed LP
• Zimmer Biomet Holdings, Inc.
• Smith & Nephew plc
• Genzyme Corporation
• Arthrex Inc
• Orthofix International BV

Report Scope

In this report, the Global Osteobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteobiologics Market, By Product

• Allografts
• Bone Marrow Aspirate Concentrate
• Bone Morphogenic Protein
• Demineralized Bone Matrices
• Plasma-Rich Protein
• Synthetic Orthobiologics
• Visco-Supplementation Products

Osteobiologics Market, By Application

• Fracture Recovery
• Maxillofacial & Dental Applications
• Osteoarthritis & Degenerative Arthritis
• Soft-Tissue Injuries
• Spinal Fusion

Osteobiologics Market, By End User

• Dental Clinics & Facilities
• Hospitals
• Research & Academic Institutes
• Specialty Clinics
• Others

Osteobiologics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteobiologics Market.

Available Customizations:

Global Osteobiologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteobiologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
  • 5.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
  • 5.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Osteobiologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Osteobiologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Osteobiologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Osteobiologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Osteobiologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Osteobiologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Osteobiologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Osteobiologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Osteobiologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Osteobiologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Osteobiologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Osteobiologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Osteobiologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Osteobiologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Osteobiologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Osteobiologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Osteobiologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Osteobiologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Osteobiologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Osteobiologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Osteobiologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Osteobiologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Osteobiologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Osteobiologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Osteobiologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Stryker Corp
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. DePuy Synthes Inc
• 15.3. Medtronic PLC
• 15.4. Osteomed LP
• 15.5. Zimmer Biomet Holdings, Inc.
• 15.6. Smith & Nephew plc
• 15.7. Genzyme Corporation
• 15.8. Arthrex Inc
• 15.9. Orthofix International BV

16. Strategic Recommendations

17. About Us & Disclaimer